Several clinical trials have been completed or are ongoing with anti-IL5 biologicals in patients with secondary eosinophilia, such as eosinophilic asthma (153), eosinophilic esophagitis (154), and EGPA (155). Here, IL5 is linked to Increased total eosinophil count.